Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L... see more

Recent & Breaking News (NDAQ:ELDN)

Novus Therapeutics Reports Third Quarter 2019 Financial Results

Business Wire November 13, 2019

Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

Business Wire October 29, 2019

Novus Therapeutics to Participate in Two Upcoming Investor Conferences

Business Wire August 29, 2019

Novus Therapeutics Reports Second Quarter 2019 Financial Results

Business Wire August 13, 2019

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

GlobeNewswire July 22, 2019

Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media

Business Wire June 10, 2019

Novus Therapeutics Reports First Quarter 2019 Financial Results

Business Wire May 14, 2019

Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

Business Wire May 2, 2019

Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market

Business Wire April 30, 2019

Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials

Business Wire April 22, 2019

Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates

Business Wire March 28, 2019

Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Business Wire February 20, 2019

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201

Business Wire February 19, 2019

Company Profile for Novus Therapeutics, Inc.

Business Wire February 15, 2019

Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201

Business Wire February 11, 2019

Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

Business Wire January 30, 2019

Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201

Business Wire January 8, 2019

Novus Therapeutics Announces Formation of Scientific Advisory Board

Business Wire December 4, 2018

Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201

Business Wire November 27, 2018

Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference

Business Wire November 15, 2018